Please login to the form below
sHPT
This page shows the latest sHPT news and features for those working in and with pharma, biotech and healthcare.
NICE set to back Parsabiv for kidney disease complication
sHPT parathyroidism is a serious condition that affects a high proportion of CKD patients receiving dialysis. ... It is estimated that only around 25% of eligible patients take cinacalcet, mainly because most people with sHPT have a substantial number of
Latest news
-
Amgen's chronic kidney disease drug Parsabiv cleared in US
Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on
-
Amgen wins European approval for Parsabiv
European regulators have approved Amgen's Parsabiv (etelcalcetide), licensing it for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ... The first new treatment to be approved for sHPT in more
-
FDA knocks back Amgen's chronic kidney disease treatment
Like its predecessor, the new calcimimetic drug - called Parsabiv ( etelcalcetide) - has been developed for the treatment of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD) who are on dialysis. ... Clinical trials also
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
PAN and DJM win prestigious Global Award
Mimpara is approved for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, and it was for this indication that the
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
